Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineerin...
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that China's National Medical Products Administ...
GSK plc (LSE/NYSE: GSK) announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibod...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
HUTCHMED (China) announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO&re...
SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, to...
Corcept Therapeutics, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab...
Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90° articulation capability, has been approved for marke...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced no...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced the co...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated wi...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10%...
Janssen-Cilag International NV, a Johnson & Johnson company, announced the European Commission (EC) approval of RYBREVANT®▼ (amivan...
© 2025 Biopharma Boardroom. All Rights Reserved.
